

## Correction

# Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids

Michael R. Martino, Manuel Gutiérrez-Aguilar, Nicole K.H. Yiew, Andrew J. Lutkewitte, Jason M. Singer, Kyle S. McCommis, Daniel Ferguson, Kim H.H. Liss, Jun Yoshino, M. Katie Renkemeyer, Gordon I. Smith, Kevin Cho, Justin A. Fletcher, Samuel Klein, Gary J. Patti, Shawn C. Burgess, and Brian N. Finck\*

\*Correspondence: [bfinck@wustl.edu](mailto:bfinck@wustl.edu)

<https://doi.org/10.1016/j.celrep.2022.111633>

(Cell Reports 39, 110733; April 26, 2022)

In the original published version of this paper, a declaration of interests was accidentally omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.

